Electrotherapy medical device maker Zynex has received US Food and Drug Administration (FDA) clearance for its NexWave device.
The NexWave device is capable of delivering three modalities of stimulation: transcutaneous electrical nerve stimulation, interferential electrical stimulation and neuromuscular electrical stimulation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Zynex CEO Thomas Sandgaard said that the combined modalities of the company’s NexWave provide doctors and clinicians a comprehensive pain therapy solution for their patients.
”We believe this new product is unique in the electrotherapy industry and provides our sales force with a competitive edge to fuel revenue generation in our already rapidly growing Zynex Medical subsidiary," Sandgaard added.
